Revolution Medicines, Inc. Warrant

NASDAQ
RVMDW
Stock
Yield per half year: -69.7%
Dividend yield: 0%

0.1062 $

0 $ 0%
0.031 $
0.76 $

Min/max per year

Share chart Revolution Medicines, Inc. Warrant

Extended chart Simple chart
Financial Markets by TradingView

About Revolution Medicines, Inc. Warrant

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

more details
Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date
2023-11-17
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
link
All parameters

Grade

Underestimation
Title Value Grade
P/S 0 0
P/BV 0.0133 10
P/E 0 0
Efficiency
Title Value Grade
ROA -25.98 0
ROE -29.33 0
ROIC 0 0
Dividends
Title Value Grade
Dividend yield 0 0
DSI 0 0
Average dividend growth 0 0
Debt
Title Value Grade
Debt/EBITDA -0.197 10
Debt/Ratio 0.0531 10
Debt/Equity 0.1294 10
Growth impulse
Title Value Grade
Yield Revenue, % -74.92 0
Yield Ebitda, % 535.75 10
Yield EPS, % 120.29 10
More

Prices

Price Min. Max. Change Changes in the industry Changes in the index
Yesterday 0.1062 $ 0 $ 0 $ 0 % 0 % 0 %
Week 0.255 $ 0 $ 0 $ -58.35 % 0 % 0 %
Month 0.0881 $ 0.1006 $ 0.255 $ 20.54 % 0 % 0 %
Three month 0.086 $ 0.031 $ 0.255 $ 23.49 % 0 % 0 %
Half a year 0.3505 $ 0.031 $ 0.4 $ -69.7 % 0 % 0 %
Year 0.2299 $ 0.031 $ 0.76 $ -53.81 % 0 % 0 %
3 years 0 $ 0.031 $ 0.9999 $ 0 % 0 % 0 %
5 years 0 $ 0.031 $ 0.9999 $ 0 % 0 % 0 %
10 years 0 $ 0.031 $ 0.9999 $ 0 % 0 % 0 %
Year to date 0.18 $ 0.031 $ 0.255 $ -41 % 0 % 0 %

Company management

Head Job title Payment Year of birth
Dr. Mark A. Goldsmith Ph.D. CEO, President & Chairman 1962 (63 years)
Mr. Jack Anders Chief Financial Officer 1977 (48 years)
Ms. Margaret A. Horn J.D. Chief Operating Officer 1963 (62 years)
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. President of Research & Development 1961 (64 years)
Ms. Xiaolin Wang Executive Vice President of Development 1971 (54 years)
Dr. Martin D. Burke M.D., Ph.D. Co-Founder & Chairman of Scientific Advisory Board
Dr. Michael A. Fischbach Ph.D. Academic Co-Founder & Member of Scientific Advisory Board 1981 (44 years)
Dr. Kevan M. Shokat Ph.D. Academic Co-Founder & Member of Scientific Advisory Board
Mr. Walter Reiher Ph.D. Chief Information Officer
Ms. Jan Smith Ph.D. Chief Scientific Officer

About company

Address: United States, Redwood City, 700 Saginaw Drive - Open in google maps, Open in yandex maps
Website: https://www.revmed.com